Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
David Krieger (Berlin, Germany), David Krieger, Silvan Vesenbeckh, Nicolas Schönfeld, Gudrun Bettermann, Holger Rüssmann, Harald Mauch, Torsten Bauer. Minimal inhibitory concentrations (MICs) of mefloquine: in vitro activity against MDR- and nonMDR-Tb strains. Eur Respir J 2015; 46: Suppl. 59, 3327

Member's Comments

No comment yet.

Related content which might interest you: Minimum inhibitory concentrations (MIC) determination of TB drugs and broad-spectrum antibiotics in M.tuberculosis with M/X/TDR Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Neuroleptic drugs as potential adjuvants in the treatment of MDR-TB: Minimal inhibitory concentrations (MICs) of different phenothiazines against M. tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB) Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/Germany Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 287-289 Year: 2015 Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 285-287 Year: 2015 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Minimal inhibiting concentration of cationic surfactants against various genotypes of mycobacterium tuberculosis (MBT) Source: International Congress 2015 – Case series and clinical conundrums in TB Year: 2015 Efficacy of moxifloxacin in TB resistant to isoniazid Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Unit of multidrug resistant tuberculosis - effect of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Features of different M.tuberculosis strains that were isolated from MDR-TB patients in Kharkiv, Ukraine Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 High proportion of fluoroquinolone mono-resistant mycobacterium tuberculosis (MTB) strains in Pakistan (2010-2012) Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015